A Comprehensive Systematic Review of Belly Fats: Pathophysiology, Clinical Implications, and Intervention Strategies

Belly fat, particularly visceral adipose tissue (VAT), presents a significant public health challenge due to its role in metabolic dysfunction and cardiovascular disease. This systematic review examines VAT’s molecular mechanisms, clinical implications, and intervention strategies. The primary objectives were to elucidate VAT’s endocrine function, assess its contribution to inflammation and insulin resistance, and evaluate effective reduction methods. A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science for studies published between 2014 and 2024. Eligible studies included randomized controlled trials, meta-analyses, and observational research on VAT-related outcomes, focusing on its metabolic and cardiovascular implications. Findings of the review indicate that VAT secretes elevated levels of pro-inflammatory cytokines, such as IL-6 and TNF-α, while reducing protective adipokines like adiponectin, creating a pro-inflammatory environment that contributes to insulin resistance, oxidative stress, and atherosclerosis. Additionally, VAT accumulation is closely linked to dyslipidemia, hypertension, and other components of metabolic syndrome, exacerbating cardiometabolic risk. Intervention strategies for VAT reduction range from lifestyle modifications to pharmacotherapies. Dietary interventions emphasizing caloric restriction, reduced refined carbohydrates, and balanced macronutrient intake, alongside structured exercise regimens incorporating both aerobic and resistance training, have demonstrated consistent efficacy in reducing VAT and improving metabolic health. Emerging pharmacotherapies, including GLP-1 receptor agonists and SGLT2 inhibitors, show promise in targeting VAT and enhancing metabolic profiles. Advances in imaging technologies, such as CT and MRI, have significantly improved VAT quantification, aiding both clinical diagnosis and personalized treatment strategies. In conclusion, targeted VAT management is essential to mitigate cardiometabolic risk. Standardized imaging protocols, comprehensive intervention strategies, and ongoing research into novel therapies are necessary to optimize VAT reduction thereby,improving long-term health outcomes.